Accenture Accelerates and 3 Stock Analyses to Track
Accenture plc (NYSE:ACN) Q4 revenue exceeded expectations and presented higher FY13 EPS guidance than predicted, causing Argus to be convinced that Accenture’s outsourcing and consulting businesses seem to be in the process of accelerating. The firm keeps a Buy rating and increases its target to $80 from $74 on the stock.
Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX): According to Sterne Agee, Allscripts is worth $15 per share, not including $85 million worth in possible cost savings able to be taken out of the business, which possibly would add $4 per share, totaling $19 per share.
Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>
Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) is believed by Piper Jaffray to be interested in hiring no one but a bank to explore a sale if all other options fail, since management is not interested in beginning at a bottom. According to Piper, while average takeout multiples in the sector indicate a $22 per share buyout price, Allscripts’s challenges may minimize the takeout price to about $14 per share. The firm continues its caution regarding today’s stock rally after Bloomberg’s report, and it maintains its Neutral rating on the stock.
Monster Worldwide, Inc. (NYSE:MWW) has begun talks with a private equity firm, according to dealReporter.
Investing Insights: Share Buybacks: Apple Kicks Off $10B Repurchase Plan, News Corp. Sells to BSkyB.